Evidence map›Paper›PMID 31907190›Full record

ArticleAntimicrobial agents and chemotherapy2020

Mechanism-of-Action Classification of Antibiotics by Global Transcriptome Profiling.

Aubrie O'Rourke, Sinem Beyhan, Yongwook Choi, Pavel Morales, Agnes P Chan, Josh L Espinoza, Chris L Dupont, Kirsten J Meyer, Amy Spoering, Kim Lewis and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 116 citations in OpenAlex.

  1. Article
  2. Article
  3. Proteostasis-targeted antibacterial strategies.Journal of microbiology (Seoul, Korea) · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Perturbation-specific transcriptional mapping for unbiased target elucidation of antibiotics.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  18. Article
  19. Review
  20. Optimizing Archaeal Lipid Biosynthesis inACS synthetic biology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Aubrie O'Rourke *Department of Human Biology, J. Craig Venter Institute, La Jolla, California, USA.ORCID 0000-0002-2890-1682
Sinem Beyhan *Department of Human Biology, J. Craig Venter Institute, La Jolla, California, USA.
Yongwook ChoiDepartment of Human Biology, J. Craig Venter Institute, Rockville, Maryland, USA.
Pavel MoralesDepartment of Human Biology, J. Craig Venter Institute, La Jolla, California, USA.
Agnes P ChanDepartment of Human Biology, J. Craig Venter Institute, Rockville, Maryland, USA.
Josh L EspinozaDepartment of Human Biology, J. Craig Venter Institute, La Jolla, California, USA.
Chris L DupontDepartment of Human Biology, J. Craig Venter Institute, La Jolla, California, USA.
Kirsten J MeyerDepartment of Biology, Antimicrobial Discovery Center, Northeastern University, Boston, Massachusetts, USA.
Amy SpoeringNovoBiotic Pharmaceuticals, Cambridge, Massachusetts, USA.
Kim LewisDepartment of Biology, Antimicrobial Discovery Center, Northeastern University, Boston, Massachusetts, USA.
William C NiermanDepartment of Human Biology, J. Craig Venter Institute, Rockville, Maryland, USA.
Karen E NelsonDepartment of Human Biology, J. Craig Venter Institute, La Jolla, California, USA kenelson@jcvi.org.
J. Craig Venter Institute · USNortheastern University · USNovoBiotic Pharmaceuticals · US

Funding

Uncultured bacteria for the discovery of novel antimicrobialsP01AI118687 · NIAID · NORTHEASTERN UNIVERSITY · PI LEWIS, KIM · 2016 to 2020
$8.9M
NIAID NIH HHS P01 AI118687
6 · The paper itself

Abstract

Antimicrobial resistance (AMR) is an ever-growing public health problem worldwide. The low rate of antibiotic discovery coupled with the rapid spread of drug-resistant bacterial pathogens is causing a global health crisis. To facilitate the drug discovery processes, we present a large-scale study of reference antibiotic challenge bacterial transcriptome profiles, which included 37 antibiotics across 6 mechanisms of actions (MOAs) and provide an economical approach to aid in antimicrobial dereplication in the discovery process. We demonstrate that classical MOAs can be sorted based upon the magnitude of gene expression profiles despite some overlap in the secondary effects of antibiotic exposures across MOAs. Additionally, using gene subsets, we were able to subdivide broad MOA classes into subMOAs. Furthermore, we provide a biomarker gene set that can be used to classify most antimicrobial challenges according to their canonical MOA. We also demonstrate the ability of this rapid MOA diagnostic tool to predict and classify the expression profiles of pure compounds and crude extracts to their expression profile-associated MOA class.

Indexed as

Anti-Bacterial AgentsAnti-Infective AgentsDrug DiscoveryEscherichia coliGene Expression ProfilingMicrobial Sensitivity TestsAnti-Bacterial AgentsAnti-Infective Agentsantibioticsantimicrobialsdereplicationdrug discoveryE. colimechanism of actiontranscriptomics

Identifiers

PMID31907190
PMCPMC7038283
OpenAlexW2999866742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.